Nordic Pharma, a subsidiary of SEVER Life Sciences, will present its innovative LACRIFILL canalicular gel at the American Academy of Ophthalmology (AAO) annual meeting in New Orleans from October 9-12, 2026. The gel is used by over 2,200 eye care providers in the U.S. to aid cataract and refractive surgery recovery and treat dry eye symptoms, benefiting over 130,000 patients so far. Recent patient surveys show high satisfaction, with 96% of cataract surgery patients and 91% overall reporting eye relief. The gel also reduces the need for eye drops and supports long-term postoperative comfort. Nordic Pharma will share clinical data and patient experience results at the event, aiming to expand awareness and use of LACRIFILL in eye care.
The story about SEVER Life Sciences and its subsidiary Nordic Pharma sharing patient data on LACRIFILL gel is presented here with Health-sector market data for context. For readers following Health-sector US stocks on Pluang, 56 of 100 stocks rose and 43 fell today. Notable movers include CVS at USD 88.77 with a 2.70% increase, Amgen at USD 413.42 with a 2.69% increase and a 60% buy order activity, and Mesoblast at USD 13.97 with a 2.65% increase. This data is as of Oct 07, 2026 21:21 WIB.
BNP Paribas lowered Hormel Foods' price target from $26 to $23, indicating a potential 16.2% upside from its current price of around $19.80. Despite a 50.5% decline in its share price over five years, Hormel Foods remains attractive for dividend inve...
Barclays initiated coverage of Becton, Dickinson and Company (BDX) with an "Underweight" rating, indicating a cautious outlook for the medical technology stock. BDX is partnering with the U.S. government to boost domestic manufacturing and strengthen...
Morgan Stanley increased its price target for Eli Lilly to $1,430 from $1,419, maintaining an Overweight rating. This new target implies a potential upside of about 20.8% from the current share price of around $1,184. The adjustment reflects updated ...
Arthur J. Gallagher expects about 6% organic growth in Q3, driven by strong client retention and new business despite easing property insurance pricing. Cantor Fitzgerald lowered its price target to $280, below the $288 average from 19 analysts who m...
Needham raised Zscaler's price target to $255, citing strong demand for AI-related cybersecurity solutions. Zscaler aims to exceed $8 billion in annual recurring revenue by fiscal 2031, driven by increasing needs to protect against AI-powered cyberat...
